These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26565561)

  • 1. The value of routine pharmacogenomic screening-Are we there yet? A perspective on the costs and benefits of routine screening-shouldn't everyone have this done?
    Veenstra DL
    Clin Pharmacol Ther; 2016 Feb; 99(2):164-6. PubMed ID: 26565561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer patients acceptance, understanding, and willingness-to-pay for pharmacogenomic testing.
    Cuffe S; Hon H; Qiu X; Tobros K; Wong CK; De Souza B; McFarlane G; Masroor S; Azad AK; Hasani E; Rozanec N; Leighl N; Alibhai S; Xu W; Issa AM; Liu G
    Pharmacogenet Genomics; 2014 Jul; 24(7):348-55. PubMed ID: 24911662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic opportunities and challenges for pharmacogenomics.
    Deverka PA; Vernon J; McLeod HL
    Annu Rev Pharmacol Toxicol; 2010; 50():423-37. PubMed ID: 20055709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review of pharmacoeconomic studies of pharmacogenomic tests.
    Beaulieu M; de Denus S; Lachaine J
    Pharmacogenomics; 2010 Nov; 11(11):1573-90. PubMed ID: 21121811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of pharmacogenomics: a value-based approach to pragmatic decision making in the face of complexity.
    Snyder SR; Mitropoulou C; Patrinos GP; Williams MS
    Public Health Genomics; 2014; 17(5-6):256-64. PubMed ID: 25278172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomics in the clinic.
    Relling MV; Evans WE
    Nature; 2015 Oct; 526(7573):343-50. PubMed ID: 26469045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomic test that predicts response to inhaled corticosteroids in adults with asthma likely to be cost-saving.
    Wu AC; Gay C; Rett MD; Stout N; Weiss ST; Fuhlbrigge AL
    Pharmacogenomics; 2015; 16(6):591-600. PubMed ID: 25880024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of cost-effectiveness analyses of pharmacogenomic interventions.
    Phillips KA; Van Bebber SL
    Pharmacogenomics; 2004 Dec; 5(8):1139-49. PubMed ID: 15584880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis in pharmacogenomics.
    Payne K; Shabaruddin FH
    Pharmacogenomics; 2010 May; 11(5):643-6. PubMed ID: 20415553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measuring the value of pharmacogenomics.
    Phillips KA; Van Bebber SL
    Nat Rev Drug Discov; 2005 Jun; 4(6):500-9. PubMed ID: 15915153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scanning the human genome and the horizon: the potential and pitfalls of pharmacogenetics and stratified medicine.
    Jennings BA; Shakespeare T; Loke YK
    Br J Gen Pract; 2015 Jun; 65(635):284-5. PubMed ID: 26009508
    [No Abstract]   [Full Text] [Related]  

  • 12. Implementation of genetics to personalize medicine.
    Chung WK
    Gend Med; 2007 Sep; 4(3):248-65. PubMed ID: 18022591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders.
    Hess GP; Fonseca E; Scott R; Fagerness J
    Genet Res (Camb); 2015 Jun; 97():e13. PubMed ID: 26030725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacogenomics: hype or hope?].
    Schwab M; Schaeffeler E; Zanger UM; Brauch H; Kroemer HK
    Dtsch Med Wochenschr; 2011 Mar; 136(10):461-7. PubMed ID: 21365522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines.
    Vegter S; Boersma C; Rozenbaum M; Wilffert B; Navis G; Postma MJ
    Pharmacoeconomics; 2008; 26(7):569-87. PubMed ID: 18563949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics.
    Phillips KA; Veenstra D; Van Bebber S; Sakowski J
    Pharmacogenomics; 2003 May; 4(3):231-9. PubMed ID: 12718713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A framework to evaluate the economic impact of pharmacogenomics.
    Stallings SC; Huse D; Finkelstein SN; Crown WH; Witt WP; Maguire J; Hiller AJ; Sinskey AJ; Ginsburg GS
    Pharmacogenomics; 2006 Sep; 7(6):853-62. PubMed ID: 16981846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine.
    Marra CA; Esdaile JM; Anis AH
    J Rheumatol; 2002 Dec; 29(12):2507-12. PubMed ID: 12465143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Facilitating clinical implementation of pharmacogenomics.
    Mrazek DA; Lerman C
    JAMA; 2011 Jul; 306(3):304-5. PubMed ID: 21771991
    [No Abstract]   [Full Text] [Related]  

  • 20. On pharmacogenomics in pharmacy benefit management.
    Russell Teagarden J; Stanek EJ
    Pharmacotherapy; 2012 Feb; 32(2):103-11. PubMed ID: 22392418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.